EVENTOS DE EURORDIS
Multi-stakeholder Symposium on Improving Patient Access to Rare Disease Therapies
An exceptional two-day event not to be missed!
24 - 25 February 2016
Brussels, Belgium
Please note that registration is required for this event.
EURORDIS and partners will bring together industry, patient leaders, academics, regulators and payers to discuss the current state of play and how to shape a more effective way to address value determination, appraisal, pricing and reimbursement of orphan medicines. In line with the EURORDIS Round Table of Companies, this symposium aims to improve patients' access to rare disease therapies throughout Europe.
Download the advanced programme (PDF, 475 KB)
Download the flyer (PDF, 842 KB)
1. Symposium Objectives
This meeting on the topic of HTA is envisaged as a two-stage process, with a second symposium in 2017 on a more consensual approach to the new solutions discussed throughout 2016. For this 1st meeting, the overarching aim is to gain common understanding and agreement on the determinants of value, and of the assessment and appraisal methods for orphan medicinal products, by:
- Bringing all participants to a common understanding of issues/challenges of access to rare disease therapies (webinar/pre-reads to be circulated before meeting);
- Sharing existing and new processes to recognise which ones work best;
- In view of the 2017 symposium, agreeing on a structured approach forward and a set of solutions to explore.
2. Register
Please make sure you register in the correct category:
- Registration form for Members of the EURORDIS Round Table of Companies, patient representatives, payers (HTA agencies and National Competent Authorities), regulators and government workers (fee waiver).
- Registration form for other pharmaceutical and biotech industry representatives, consultants, investors, health care professionals, academics and researchers (950 € for pharmaceutical industry that are not ERTC members, consultants, investors; 350 € for health care professionals, academics and researchers).
3. Venue
Boulevard Adolphe Max 118 - 126, Brussels, Belgium
Tel. + 32 2 278 01 00
Metro Station: Rogier
4. Official Partners
5. Programme Committee Members & Advisors
Members of the Programme Committee:
Lieven Annemans
Professor of Health Economics
Gent University
Belgium
Professor of Health Economics
Gent University
Belgium
Ri De Ridder
Director-General of Healthcare
RIZIV-INAMI
Belgium
Director-General of Healthcare
RIZIV-INAMI
Belgium
Karen Facey
Evidence Based Health Policy Consultant
Glasgow University
United-Kingdom
Evidence Based Health Policy Consultant
Glasgow University
United-Kingdom
Ruediger Gatermann
Director, Healthcare Policy and External Affairs Europe
CSL Behring
Germany
Director, Healthcare Policy and External Affairs Europe
CSL Behring
Germany
Josie Godfrey
Public Policy and External Affairs
Sobi - Swedish Orphan Biovitrum AB
United-Kingdom
Public Policy and External Affairs
Sobi - Swedish Orphan Biovitrum AB
United-Kingdom
Laura Gutierrez
Senior Director European Government Relations and Public Policy
Celgene
Belgium
Senior Director European Government Relations and Public Policy
Celgene
Belgium
Adam Heathfield
Co-chair EFPIA - EuropaBio Task Force
Senior Director, International Policy
Pfizer
United-Kingdom
Co-chair EFPIA - EuropaBio Task Force
Senior Director, International Policy
Pfizer
United-Kingdom
Christian Hill
Managing Director
Map Biopharma
United-Kingdom
Managing Director
Map Biopharma
United-Kingdom
Virginie Hivert
Therapeutic Development Director
EURORDIS
France
Therapeutic Development Director
EURORDIS
France
Yann Le Cam
Chief Executive Officer
EURORDIS
Europe
Chief Executive Officer
EURORDIS
Europe
Vinciane Pirard
co-chair EFPIA - EuropaBio Task Force
Director Public Affairs
Genzyme Europe BV
Belgium
co-chair EFPIA - EuropaBio Task Force
Director Public Affairs
Genzyme Europe BV
Belgium
Advisors to the Programme Committee:
François Houÿez
Treatment Information and Access Director / Health Policy Advisor
EURORDIS
France
Treatment Information and Access Director / Health Policy Advisor
EURORDIS
France
Kristina Larsson
Head of Office – Orphan Medicinal Products
European Medicines Agency (EMA)
United-Kingdom
Head of Office – Orphan Medicinal Products
European Medicines Agency (EMA)
United-Kingdom
Solange Rohou
ADAPT SMART consortium (EMA)
Director Regulatory Affairs
AstraZeneca
France
ADAPT SMART consortium (EMA)
Director Regulatory Affairs
AstraZeneca
France
Ad Schuurman
Head of the Business Contact Centre & International Affairs
National Health Care Institute (former CVZ)
The Netherlands
Head of the Business Contact Centre & International Affairs
National Health Care Institute (former CVZ)
The Netherlands
Cees Smit
Patient advocate
European Genetic Alliances Network (EGAN)
The Netherlands
Patient advocate
European Genetic Alliances Network (EGAN)
The Netherlands
Chris Sotirelis
Patient advocate
UK Thalassaemia Society
United-Kingdom
Patient advocate
UK Thalassaemia Society
United-Kingdom
6. Hotel & Travel Information
EURORDIS has booked a block of rooms and has negotiated special rates at the Hotel Le Plaza for the nights of 24 and 25 February 2016. If you wish to make a reservation at the Hotel Le Plaza, please contact the reservation department directly (Tel. +32 2 278 01 00 / reservations@leplaza.be).
Single occupancy: 195 Euros per night including breakfast*
Double occupancy: 224 Euros per night including breakfast*
*City Tax is not included in the room rate - a supplement of 9.85 € per room per night will be applied
*City Tax is not included in the room rate - a supplement of 9.85 € per room per night will be applied
Details of other hotels close to the venue will be provided here soon.
7. Preparatory documents
- ISPOR Milan Rare Disease Special Interest Group Presentation (11/18/2015)
- Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group (2015)
- EVIDEM - Rare Disease Study 2015
- Introduction to Health Technology Assessment
- The role of Patient Advocacy
- Eunethta website
8. Preparatory webinar
Date: Thursday 4th February 2016, afternoon (time tbc.)
Speakers: François Houÿez, Treatment Information and Access Director/Health Policy Advisor at EURORDIS, and another speaker tbc.
9. Contact
Please address all questions to Anne-Mary Bodin at anne-mary.bodin@eurordis.org
No hay comentarios:
Publicar un comentario